Slide item 1

Keselamatan Menjadi Prioritas Utama dalam pelaksanaan kegiatan produksi radioisotop dan radiofarmaka

Keselamatan pekerja, masyarakat dan lingkungan merupakan faktor utama dalam setiap kegiatan di PTRR

Readmore....
Slide item 2

Keselamatan Menjadi Prioritas Utama dalam pelaksanaan kegiatan produksi radioisotop dan radiofarmaka

Keselamatan pekerja, masyarakat dan lingkungan merupakan faktor utama dalam setiap kegiatan di PTRR

Readmore....
Slide item 3

Keselamatan Menjadi Prioritas Utama dalam pelaksanaan kegiatan produksi radioisotop dan radiofarmaka

Keselamatan pekerja, masyarakat dan lingkungan merupakan faktor utama dalam setiap kegiatan di PTRR

Readmore....

Institutions which have cooperation with PRR among others :

Cooperation with the University of Padjadjaran (UNPAD)
The Cooperation Agreement between PTRR-BATAN and the Medical Faculty of UNPAD Number 458/KS 00 01/IV/2008 and Number 221/H6.7.FK/Kep/DN/2008 is dated 24 April 2008 and signed in  Bandung. The cooperation with the Medical Faculty of UNPAD has the objective to increase the utilization and development in Education, Research and Development of Nuclear Science and Technology in the field of Health in connection with diagnosis and therapy in development of the MRI Contrast Agents which also involves FMIPA-UNPAD. The role of PRR besides connected to synthesis also utilizes nuclear technique for bio-distribution testing towards test mice. Several MRI Contrast Agents that have entered the pre-clinical testing, among them are Gd-DTPA, Gd-DTPA-HAS and Gd-DTPA-Dendrimer-Nimotuzumab (Ninotuzumab is a monoclonal anti-body which is specific for cancer of the brain, ovaries and colon).

Cooperation Agreement between  PTRR-BATAN and the Pharmacy Faculty – UNPAD Number 459/KS 00 01/IV/2008 and Number 1405/H6.7/ FF/PP/2008 dated 24 April 2008 and signed in  Bandung. The Cooperation with the Pharmacy Faculty of UNPAD is regarding Education, Research and Development of Nuclear Science and Technology in Pharmacy and Radiopharmaceuticals which are connected in conducting testing to fevicordin, a natural compound of the results of isolation of the mahkota dewa fruit which is conducted in the Faculty of Pharmacy UNPAD. The testing which is conducted is the interaction of the compound towards the target molecule, estradiol receptor, which is expressed as breast cancer by using the radioligand  binding assay technique (RBA).

The Cooperation Agreement between PTRR-BATAN and Faculty of MIPA-UNPAD Number 460/KS 00 01/IV/2008 and Number 1277/H6.7.FMIPA/KP/2008 dated 24 April 2008 and signed in Bandung. The Cooperation with the Faculty of Pharmacy UNPAD has the objective to increase the utilization and development of Nuclear Science and Technology in the field of Physics, Chemistry, Mathematics and Statistics.

Cooperation with the University of Indonesia (UI)
The cooperation agreement between PTRR-BATAN and the Faculty of MIPA-University of Indonesia, Number 1639/KS 00 01/VII/2008 and Number 1150/PT.02.H4.FMIPA/G/2008 dated 16 December 2008 and signed in Depok. This agreement has the objective to increase the utilization  and development in Education, Research and Development of Nuclear Science and Technology in the field of Physics, Chemistry, Biology and Pharmacy. The activities which involve Physics-UI is the preparation of TPS for the need of the I-125 Seed Brachytherapy. Whereas with Chemistry-UI is the development of gold nano-particle, 198Au, which is packaged in dendrimer for the need of nano device brachytherapy. The activities involving the Pharmacy-UI is in connection with development of conjugation ‘monoclonal antibody’ with ‘bi-chelating agents’.

Cooperation with the hospital (RS) MRCCC Siloam Hospital Semanggi
Cooperation agreement between  PTRR-BATAN and Mochtar Riady Comprehensive Cancer Siloan Hospitals Semanggi Number : 1766/KS 00 01/VIII/2011 which is signed by the Head of PRR-BATAN with the Executive Director of MRCCC Siloam Semanggi on the 10th  August 2011, in Jakarta. This Agreement  is regarding Research and Development as well as utilization of radioisotope and radiopharmaceuticals in the field of health for services in nuclear medicine, radiotherapy and radio-diagnostics. Besides that for trial test of radiopharmaceuticals and brachytherapy sealed source in connection with pre clinical testing and clinical testing.

Cooperation with the Dharmais Cancer Hospital
A Note of Understanding  of the Deputy for PHLPN with the Executive Director of the Dharmais Cancer Hospital regarding cooperation activities in research, especially  radiopharmaceutical therapy and brachytherapy, has been signed on 15th January 2008 until 14 January 2013 and until now is still ongoing. The results of the research is : Early detection of Ovary cancer  (Kit IRMA) CA-15.3 and I-131-MIBG has been conducted to the patient with accurate results of diagnosis. Basically BATAN and the Cancer Hospital have made an agreement regarding Research, Development and Utilization of Nuclear Science and Technology in the Field of Health. Besides that BATAN with the Dharmais Cancer Hospital also made an agreement regarding supervision of the operation of the cyclotron, the production and QC of the Radiopharmaceutical PET. Supervision activities are conducted in turns on certain days every week in a certain working hour    ( 3 – 4 jam).

Cooperation with PT. Kimia Farma Persero
This cooperation is contained in agreements Number 1036/KS 00 01/IV/2011 and Number 35/KF/PRJ/IV/2011 dated 28 April 2011 which was signed in the Building of PT.Kimia Farma (Persero) Tbk and attended by the Head of PTRR BATAN Abdul Muthalib, Executive Director PT. Kimia Farma M. Syamsul Arifin, Commission er of PT. Kimia Farma Prof. Dr. Wahono Sumaryono, several members of the expert staff and employees of PRR BATAN as well as a number of employees of PT. Kimia Farma.

The intention and objective of this cooperation is to give an opportunity to PT Kimia Farma to be able to utilize the results of research and development optimally which are produced by PTRR in the form of products that could be used for diagnostics  as well as therapy in accordance to the valid regulations, and empowerment as well as development in the technology in production  of radioisotope and radiopharmaceuticals in order to produce a product to fulfill the needs of hospitals, the medical society and other parties which need them, which are:
– Radiopharmaceutical Kit : MIBI, MDP, DTPA Kits
– Labeled compound  Sm-153-EDTMP
– Labeled compound  I-131-MIBG
– I-125 Seed Brachytherapy

The Note of Understanding between the University of Padjadjaran and the National Nuclear Energy Agency with PT. Kimia Farma (Persero) Tbk.
Number : 1488/UN6.RKT/TU/2011 (UNPAD – First Party)
Number : 1042/KS 00 01/VIII/2011 (BATAN – Second Party)
Number : 74/KF/PRJ/VIII/2011 (PT.Kimia Farma,Tbk – Third Party)
The signing was conducted on Wednesday dated 10th August 2011 by the Rector of the University of Padjadjaran, Head of BATAN and Executive Director of PT. Kimia Farma, Tbk.

The purpose of this Note of Understanding is for empowerment, utilization and marketing as well as distribution of the products from results of research which have been produced and developed by the First Party and Second Party (shall further be mentioned as “product”) which could be used for diagnostic and therapy purposes in accordance to the valid laws and regulations as well as to give an added value for the interests of the parties as well as to increase the welfare of the people. Besides that it is for the utilization of the laboratory facilities owned by the First Party and Second Party for research, production and development by the Third Party. The utilization of the factory facilities and laboratory owned by Third Party for research, production and development by First Party and Second Party.

Cooperation with PT. Batan Teknologi (Persero)

DIn the frame of Quality Testing  (QC)   Mo-99 from the Results of LEU (Low Enrichment Uranium) controlled enrichment Uranium fission).

Cooperation with the Bandung Institute of Technology (ITB)

The cooperation agreement between  PTRR-BATAN and the Facuilty of MIPA-ITB Bandung, Number 910/KS 00 01/IX/2008 and Number 1983/H.2.3.1/HM/2008 dated  11 September 2008 and signed in Bandung. This agreement has the objective to increase the utilization and development in Education, Research and Development of Nuiclear Science and Technology in Physics Sciences, Natural Sciences and Computation Sciences.  The activities involve the Chemistry-ITB in development of labeled compounds, the 32P-ATP and the 32P-DNA for the need of  ”moleculer tracer” in biotechnology research and ’life science’. Whereas the activities with Physics-ITB is the preparation of  TPS for I-125 ’seed brachytherapy’.

The Cooperation Agreement between the Pharmacy School – ITB Number 911/KS 00 01/IX/2008 and Number 2486/K01.15/KS/2008 dated 11 September 2008 and signed in Bandung.  This agreement has the objective for increasing the utilization and development in Education, research and development of Nuclear Science and Technology in the field of Pharmacy and Radio-pharmacy. This activity is to conduct testing towards natural material compounds isolated by the Pharmacy-ITB, which is falerin of the results of isolation from the peels of mahkota dewa by using the Assay Binding radioligand  technique (RBA).  Besides that, conducting labeling to the differentiation of the porphyrin compound which is synthesized by the Pharmacy-ITB, for preparation of cancer therapy  radiopharmaceutical.

Cooperation with the Office for Quality Testing and  Certification of Animal Medicine (BPMSOH)

Ministry for Agriculture : Cooperation in preparation and storage of Cell Lines.

Center for Radioisotope and Radiopharmaceuticals Technology

Visitor Counter